CNS Pharmaceuticals, Inc.

Stage 3 · Topping · week 1

As of Oct 22, 2026, CNS Pharmaceuticals is in Stage 3, the topping phase, now in its first week (since Oct 21, 2026). It closed at $4.75, 44.7% below its 52-week high and above its 200-day average, which is falling.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. More about the company

$4.75

-1.55% today

$6.9M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is CNSP early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 92w

S4 24w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 1w → S4 11w → S1 4w → S2 5w → S3 1w → S4 92w → S1 6w → S4 24w → S1 12w → S4 1w → S3 1w → S2 9w → S3 1w current

Total tracked: 166 weeks across 13 stage runs.

CNSP among Biotechnology342nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…342	CNSPCNS Pharmaceuticals, Inc.	Stage 3 · wk 1	25	−7.8%

vs 52W High

-44.7%

$2.13 lo$8.59 hi

44.7% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 1

1w13w26w

Week 1, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

2.7%

200 DMA: $4.62 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

1.66x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-7.8%

-9.2%

+92.3%

YTD

-10.4%

-47.2%

Scan Membership

Breakout Watch

Latest: 2023-12-05

2 appearances in last 60 days. First seen: 2021-02-08.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 1 · Vol 1.66x

2026-10-21S32→3

Wk 1 · Vol 0.00x

2026-10-20S2

Wk 9 · Vol 0.00x

2026-10-19S2

Wk 9 · Vol 0.93x

2026-10-16S2

Wk 9 · Vol 2.30x

2026-10-15S2

Wk 9 · Vol 0.15x

2026-10-14S2

Wk 8 · Vol 0.00x

2026-10-13S2

Wk 8 · Vol 2.46x

2026-10-12S2

Wk 8 · Vol 1.05x

2026-10-09S2

Wk 8 · Vol 0.20x

2026-10-08S2

Wk 8 · Vol 0.30x

2026-10-07S2

Wk 7 · Vol 0.45x

Moving averages & range

50 DMA

$5.43

200 DMA

$4.62

52W High

$8.59

52W Low

$2.13

5D Low

$4.75

Resistance levels (recent highs)

20d High

$5.43

60d High

$6.01

120d High

$7.84

250d High

$8.35

Next resistance

+14.3%

to 20d High

ROE

-106.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.4

CNS Pharmaceuticals: quick answers

What stage is CNS Pharmaceuticals in?

As of Oct 22, 2026, CNS Pharmaceuticals (CNSP) is in Stage 3, the topping phase. It entered Stage 3 on Oct 21, 2026 and is in its first week there. What the four stages mean

Is CNS Pharmaceuticals in an uptrend?

Its uptrend has stalled. CNS Pharmaceuticals is in Stage 3, the topping phase that follows an advance. It trades 2.7% above its 200-day average, which is falling.

How far is CNS Pharmaceuticals from its 52-week high?

CNS Pharmaceuticals closed at $4.75 on Oct 22, 2026, 44.7% below its 52-week high of $8.59. Its 52-week low is $2.13.

How has CNS Pharmaceuticals performed over the past year?

As of Oct 22, 2026, CNS Pharmaceuticals is down 47.2% over the past year and down 10.4% so far in 2026.

Which sector and industry is CNS Pharmaceuticals in?

CNS Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.